The poster presented by Celtic Pharmaceutical Holdings, L.P. (Celtic Pharma) and Neurobiological Technologies Inc. (Nasdaq: NTII) at the just concluded 11th Annual Meeting of the Society For Neuro-Oncology (SNO) in Orlando included the interim report of an open-label extension study as part of an ongoing Phase III clinical program for XERECEPT® (corticorelin acetate injection).
The said Phase III trial is an open-label extension study evaluating XERECEPT®'s long-term safety and tolerability as a new potential treatment for peritumoral brain edema (PBE), or tumor-related brain swelling.
Find more details from the press release.XERECEPT® is an investigational new drug that may present a steroid-sparing alternative to dexamethasone.
Dexamethasone is currently the standard treatment for PBE, but is associated with debilitating side effects including vision problems, muscle and bone loss, impaired wound healing and opportunistic infections.
Preclinical studies have also shown dexamethasone may increase brain tumor cell resistance to chemotherapy, inhibiting the efficacy of these targeted cancer therapies.
Comment Preview